SCHEMBL31493

SCHEMBL31493

COC(=O)c1ccc(F)c([N+](=O)[O-])c1

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
VCAM1 P19320 1/20 0.62
WDR5 P61964 1/20 0.60
ITGB1 P05556 1/20 0.56
ITGA5 P08648 1/20 0.56
ALDH1A1 P00352 3/20 0.53
HPGD P15428 2/20 0.53
NPSR1 Q6W5P4 1/20 0.53
THRB P10828 1/20 0.52
LMNA P02545 1/20 0.51
MITF O75030 1/20 0.51
KMT2A Q03164 2/20 0.50
ABL1 P00519 1/20 0.50
BCR P11274 1/20 0.50
MEN1 O00255 1/20 0.50
HIF1A Q16665 1/20 0.50
PKM P14618 1/20 0.49
POLB P06746 1/20 0.49
MAPT P10636 1/20 0.49
MAPK1 P28482 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29564693 1.00 VCAM1 (0.62) VCAM1WDR5ITGB1ITGA5ALDH1A1
SCHEMBL31274559 0.92 VCAM1 (0.54) VCAM1WDR5ITGB1ITGA5ALDH1A1
SCHEMBL2948960 0.88 ERN1 (0.60) VCAM1WDR5ITGB1ITGA5ALDH1A1
SCHEMBL29891438 0.88 ERN1 (0.60) VCAM1WDR5ITGB1ITGA5ALDH1A1
SCHEMBL5934 0.87 VCAM1 (0.58) VCAM1WDR5ALDH1A1HPGDNPSR1
SCHEMBL29556186 0.87 VCAM1 (0.58) VCAM1WDR5ALDH1A1HPGDNPSR1
SCHEMBL28566263 0.86 WDR5 (0.60) WDR5ALDH1A1HPGDLMNAKMT2A
SCHEMBL27715574 0.86 VCAM1 (0.54) VCAM1WDR5ITGB1ITGA5ALDH1A1
SCHEMBL28554330 0.85 MEN1 (0.69) WDR5ALDH1A1LMNAKMT2AABL1
SCHEMBL5734347 0.85 VCAM1 (0.68) VCAM1ALDH1A1HPGDNPSR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1251 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116348115-B Combination of antibody-drug conjugate and PARP1 selective inhibitor ASTRAZENECA UK LTD. (GB) 2026-05-26 CN disclosed
WO-2026087635-A1 DIHYDRO BENZOXAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2026-04-30 WO disclosed
US-12606555-B2 Chemical compounds ASTRAZENECA AB (SE) 2026-04-21 US disclosed
US-12600719-B2 Salt inducible kinase inhibitors THE GENERAL HOSPITAL CORPORATION (US) 2026-04-14 US disclosed
EP-4722208-A1 NOVEL BENZAMIDE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Samjin Pharmaceutical Co., Ltd. (KR) 2026-04-08 EP disclosed
US-12590306-B2 Processes for preparing phosphorodiamidate morpholino oligomers via fast-flow synthesis SAREPTA THERAPEUTICS, INC. (US) 2026-03-31 US disclosed
EP-4384268-B1 SMALL MOLECULE UREA DERIVATIVES AS STING ANTAGONISTS CURADEV PHARMA PVT LTD (IN) 2026-03-18 EP disclosed
US-12552808-B2 Diol desymmetrization by nucleophilic aromatic substitution AMGEN INC. (US) 2026-02-17 US disclosed
US-20260042747-A1 KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF ALIVEXIS, INC. (JP) 2026-02-12 US disclosed
EP-4225739-B1 PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS MERCK SHARP & DOHME LLC (US) 2026-01-21 EP disclosed
EP-0543865-A1 BENZAMIDE DERIVATIVES RHONE-POULENC RORER LIMITED (GB) 1993-06-02 EP disclosed
US-5159114-A Anticholesterol agents RHONE-POULENC SANTE (FR) 1992-10-27 US disclosed
WO-1992003412-A2 BENZAMIDE DERIVATIVES RHONE-POULENC RORER LIMITED (GB) 1992-03-05 WO disclosed
EP-0424194-A2 Benzanilide derivatives and their use as anti-atherosclerotic agents RHONE-POULENC SANTE (FR) 1991-04-24 EP disclosed
US-4957912-A ANTIBIOTICS MERCK & CO., INC. (US) 1990-09-18 US disclosed
US-4868347-A SOLVENT EXTRACTION BAYER AKTIENGESELLSCHAFT (DE) 1989-09-19 US disclosed
US-4665083-A ANTIDEPRESSANT, ANTIEPILEPTIC, SPASMOLYTIC, ANTIPARKINSONIC EGIS GYOGYSZERGYAR (HU) 1987-05-12 US disclosed
US-4226866-A BACTERICIDES, ACYLATION MERCK & CO., INC. (US) 1980-10-07 US disclosed
US-4207234-A 4-Unsubstituted azetidinone derivatives and process for preparation thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1980-06-10 US disclosed
US-4086423-A CEPHALOSPORINS, CYCLOADDITION OF GLYCINE DERIVATIVE TO THIAZINE COMPOUND MERCK & CO., INC. (US) 1978-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12590306-B2 Processes for preparing phosphorodiamidate morpholino oligomers via fast-flow synthesis RRM2B, MRPL21, RRM2 VCAM1 3925/4885WDR5 1519/4885ITGB1 151/4885
US-12600719-B2 Salt inducible kinase inhibitors GRK6, SGK1, CSNK1A1 VCAM1 2801/4885WDR5 1360/4885ITGB1 3686/4885
US-12552808-B2 Diol desymmetrization by nucleophilic aromatic substitution MCL1, BAK1, BCL2 VCAM1 1178/4885WDR5 4810/4885ITGB1 1582/4885
US-12606555-B2 Chemical compounds PARP1, PARP11, PARP12 VCAM1 2019/4885WDR5 968/4885ITGB1 2196/4885
US-20260042747-A1 KIT INHIBITORS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF KIT, LTK, HRH3 VCAM1 923/4885WDR5 2418/4885ITGB1 1105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.